Livzon Pharmaceutical Group Inc.

Livzon Pharmaceutical Group Inc.

Livzon Pharmaceutical Group — publicly listed in Shenzhen and Hong Kong — operates as a vertically integrated pharmaceutical company focused on branded generics, innovative drugs, and active pharmaceutical ingredient (API) manufacturing. Its founding dates to 1985, when it began as a state-owned enterprise in Zhuhai, China; it has since expanded globally with a corporate presence in London and R&D/commercial hubs in San Francisco, Cambridge, Boston, Waltham, Washington, Munich, Stockholm, Wilmington, and Chicago. The group's investment strategy spans internal R&D programs, licensing deals, and joint ventures across five therapeutic areas: digestive health, psychiatric/neurological, assisted reproductive, anti-infective, and oncology. Key platforms include microsphere long-acting injection technology (Microsphere platform), monoclonal antibodies (via Livzon Bio), and a central AI/ML research unit applying machine learning to formulation design and clinical trial optimization. Confirmed pipeline candidates include JP-1366 for Helicobacter pylori eradication, LPM7100328 (oral GnRH antagonist for assisted reproduction), NS-041 for depression, and brexpiprazole microsphere for schizophrenia, all per company press releases and regulatory filings (2025–2026). Headcount and total deployment figures are not publicly disclosed. However, the company operates at least five dedicated R&D subsidiaries in China plus three international affiliates. Recent operational activity includes May 2026: Announced a Phase III clinical trial completion for LPM7100328 (oral GnRH antagonist) in assisted reproduction, reported via a company press release. Livzon's structural differentiator is its dual public listing on the Shenzhen Stock Exchange (000513.SZ) and Hong Kong Stock Exchange (01530.HK), which provides governance transparency and a direct equity link to China's capital markets — unusual for a global pharmaceutical company with a London-based headquarters. This hybrid structure allows it to fund R&D via public offerings while maintaining centralized control over a diversified therapeutic pipeline.